We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Guidance for people with symptoms of a respiratory infection including COVID-19, or a positive test result for COVID-19.
Find out about the symptoms of COVID-19, what to do if you or your child has them and when to get medical help.
Information for clinicians and patients.
Background information and advice on coronavirus (COVID-19) for health and care professionals.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
This guidance provides information on COVID-19 in homelessness, domestic abuse refuge, respite room and asylum seeker accommodation settings.
Clinical advice on West Nile virus including symptoms, diagnosis and epidemiology.
Information for patients, public and health care professionals.
Travel and clinical advice on Cyclospora including characteristics, symptoms, diagnosis and epidemiology.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine etrasimod (Velsipity) to treat people with moderately to severely active ulcerative colitis.
Information to assist with differentiating Lyme disease from other causes of rash, neurological or non-specific symptoms.
If your company is in difficulty, it's important to maintain good mental health.
How to use a case-control study to evaluate your digital health product.
This article will expand on the existing analysis published in the fortnightly Winter Coronavirus (COVID-19) Infection Study data tables to look more in depth at trends in self-reported symptoms of COVID-19, including ongoing symptoms and associated risk factors.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).